Citadel Advisors’s Damora Therapeutics DMRA Stock Holding History
Bought
Maintained
Sold
Other funds holding DMRA
Citadel Advisors's DMRA Position: Q3 2026 in Review
Citadel Advisors increased its Damora Therapeutics (DMRA) stake by 133% in Q3 2026, buying an estimated $6.27M and bringing the position to 388,042 shares worth $8.26M. The position accounts for ﹤0.01% of the portfolio, ranked #3957.
Citadel Advisors first reported a position in DMRA in Q1 2023 and has held it in 7 quarters since. 115 funds tracked by Wall St. Rank hold DMRA as of Q3 2026.
- Citadel Advisors held 388,042 shares of Damora Therapeutics worth $8.26M as of Q3 2026.
- Citadel Advisors bought 221,695 Damora Therapeutics shares in Q3 2026, an estimated $6.27M.
- Damora Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q3 2026, its #3957 holding.
- Citadel Advisors first reported a position in Damora Therapeutics in Q1 2023 and has held it in 7 quarters since.
- 115 funds tracked by Wall St. Rank held Damora Therapeutics as of Q3 2026.
Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.